medigraphic.com
Colegio de Medicina Interna de México.

2007, Número 1

<< Anterior Siguiente >>

Med Int Mex 2007; 23 (1)


Enfermedad de Creutzfeldt-Jakob

Blumenkron D, Guerrero P, Ramiro M

Idioma: Español
Referencias bibliográficas: 61
Paginas: 34-46
Archivo PDF: 309.44 Kb.


RESUMEN

La enfermedad de Creutzfeldt-Jakob es la encefalopatía espongiforme más común en el ser humano. A partir de la década de 1980, y tras el aumento en la incidencia de la “enfermedad de las vacas locas” en Inglaterra, se han realizado múltiples estudios en los que se ha intentado determinar su posible trasmisión entre especies. Las encefalopatías son causadas por moléculas denominadas priones, sustancias que pueden propagarse en un mismo huésped y trasmitirse a otro, con periodos de incubación prolongados. Se han planteado otras teorías acerca del origen de las encefalopatías espongiformes, entre ellas la de las partículas virales, o bien, que la proteína priónica sólo es un receptor para un virus. En este artículo se revisan la fisiopatología, la genética, la epidemiología, las características clínicas, los criterios diagnósticos y el tratamiento de la enfermedad de Creutzfeldt-Jakob.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Prusiner SB. Molecular biology of prion disease. Science 1991;252:1515-22.

  2. Griffith JS. Self replication and scrapie. Nature 1969;215:1043-4.

  3. Cuillé J, Chelle PL. La maladie dite tremblante du mouton estellé inoculable? Comptes Rendus Acad Sci 1936;203:1552-4.

  4. Chandler RL. Encephalopathy in mice produced by inoculation with scrapie brain material. Lancet 1961;1:1378-9.

  5. Manuclidis L. Dementias, neurodegeneration and viral mechanisms of disease from the perspective of human transmissible encephalopathies. Ann NY Acad Sci 1994;724:259-81.

  6. Belay ED, Maddox RA, Gambetti Pierluigi, et al. Monitoring of occurrence or emerging forms of Creutzfeldt-Jakob disease in the United States. Neurology 2003;69:173-81.

  7. Journal of the house of commons 1755;27:87.

  8. Besnoit C, Morel C. Note sur les lesions nerveuses de la tremblante du mouton. Rev Vet 1898;23:397-400.

  9. Dickinson AG, Fraser H. An assessment of the genetics of scrapie in sheep and mice. In: Prusiner SB, editor. Slow transmissible diseases of the nervous system. Vol. 1. New York: Academic press, 1979:367-86.

  10. Alper T, Cramp WA. Does the agent of scrapie replicate without nucleic acid? Nature 1967;214:761-4.

  11. Gajdusek DC, Zigas V. Degenerative disease of the central nervous system in New Guinea: epidemic occurrence of “kuru” in the native population. N Engl J Med 1957;257:974-8.

  12. Creutzfeldt HG. Über eine eigenartige herdförmige erkrankung des zentralnervensystems. In: Nissl F, Alzheimer A, editors. Histologische und histopathologische arbeiten úber die grosshirnrinde. Jena: Gustav Fisher, 1921;6:1-48.

  13. Jakob A. Über eigernartige erkrankungen des zentralnervensystems mit bemerkenswerten anatomischen befunde (spastische pseudosklerose-encephalo-myelopathie). Deutsche Zeitschrift für Nervenheilkunde 1921:132-46.

  14. Kretzschmar HA. Human prion disease (spongiform encephalopathies). Arch Virol (Suppl) 1993;7:261-93.

  15. Gibbs CJ, Gajdusek DC, Asher DM, et al. Creutzfeldt-Jakob disease (spongiform encephalopathy): transmission to the chimpanzee. Science 1968;161:338-9.

  16. Prusiner SB. Prions. Sci Am 1984;48-57.

  17. Will RG, Ironside JW, Zeidler M, et al. A new variant of Creutzfeldt-Jakob disease in UK. Lancet 1996;347:921- 7.

  18. Stahl N, Baldwin MA, Teplow DB, et al. Structural studies of the scrapie prion protein using mass spectrometry and amino acids sequencing. Biochemistry 1993;32:1991-2002.

  19. Haywood AM. Transmissible spongiform encephalopathies. N Engl J Med 1997;337:1821-8.

  20. Prusiner SB. Prion diseases and the BSE crisis. Science 1997;278:245-57.

  21. Kocisko DA, Priola SA, Raymond GJ, et al. Species specificity in the cell-free conversion of prion proteins in their proteaseresistant forms: a model for the scrapie species barrier. Proc Natl Acad Sci USA 1995;92:3923-7.

  22. Gasset M, Westaway D. Los priones y su biología. Rev Neurol 2000;31(2):129-32.

  23. Dalsgaard N. Prion diseases. An overview. APMIS 2002;110(1):3-13.

  24. Hamaguchi T, Kitamoto T, Sato T, et al. Clinical diagnosis of MM2-type sporadic Creutzfeldt-Jakob disease. Neurology 2005;64:643-8.

  25. Goldfarb LG, Korenzyn AD, Brown P, et al. Mutation in codon 200 of scrapie amyloid precursor gene linked to Creutzfeldt-Jakob disease in Sephardic Jews of Libyan and no-Libyan origin. Lancet 1990;336:637-8.

  26. Meiner Z, Gabszon R, Prusiner SB. Familial Creutzfeldt-Jakob disease. Codon 200 prion disease in Lybian jews. Medicine 1997;76:227-37.

  27. Goldfarb LG, Petersen RB, Tabaton M, et al. Fatal familial insomnia and familial Creutzfeldt-Jakob disease: disease phenotype determined by a DNA polymorphism. Science 1992;258:806-8.

  28. Patry D, Curry B, Easton D. Creutzfeldt-Jakob disease (CJD) after blood product transfusion from a donor with CJD. Neurology 1998;50:1872-3.

  29. Wilson K, Ricketts M. The success of precaution? Managing the risk of transfusion transmission of variant Creutzfeldt-Jakob disease. Transfusion 2004;44:1475-8.

  30. Johnson R, Gibbs C. Creutzfeldt-Jakob disease and related transmissible spongiform encephalopathies. N Engl J Med 1998:339:1994-2004.

  31. Brown P, Preece M, Brandel JO, et al. Iatrogenic Creutzfeldt-Jakob disease at the millennium. Neurology 2000;55:1075-81.

  32. Swerdlow AJ, Higgins CD, Adlard P. Creutzfeldt-Jakob disease in United Kingdom patients treated with human pituitary growth hormone. Neurology 2003;61:783-91.

  33. Ladonaga A, Puopolo M, Croes EA. Mortality from Creutzfeldt- Jakob disease and related disorders in Europe, Australia and Canada. Neurology 2005;64:1586-91.

  34. Pocchiari M, Puopolo M, Croes EA, et al. Predictors of survival in sporadic Creutzfeldt-Jakob disease and other transmissible spongiform encephalopathies. Brain 2004;127:2348-59.

  35. Salazar AM, Masters CL, Gajdusek DC, et al. Syndromes of amyotrophic lateral sclerosis and dementia: relation to transmissible Creutzfeldt-Jakob disease. Ann Neurol 1983;14:17-26.

  36. Worrall BB, Rowland LP, Chin SM, et al. Amyotrophy in prion diseases. Arch Neurol 2000;57:33-38.

  37. Niewiadomska M, Kulczycki J, Wochnick-Dyjas D, et al. Impairment of the peripheral nervous system in Creutzfeldt-Jakob disease. Arch Neurol 2002;59:1430-6.

  38. Masters CL, Harris JD, Gajdusek DC, et al. Creutzfeldt-Jakob disease. Patterns of worldwide occurrence and the significance of familial and sporadic clustering. Ann Neurol 1979;5:177-88.

  39. Cathala F, Brown P, Castaigne P. La maladie de Creutzfeldt-Jakob en France continentale etude retrospective de 1968-1977. Rev Neurol 1979;5:439-54.

  40. Concerted action of the EU. Surveillance of Creutzfeldt-Jakob disease in the European community. Minutes of the second meeting in Rome July 3, 1993, and the third meeting in Paris, April 29-30,1994.

  41. Concerted action of the EU. Surveillance of Creutzfeldt-Jakob disease in the European community. Minutes of the meeting in Amsterdam, June 12-13, 1998.

  42. Brandel JP, Dealsnerie-Laupretre N, Laplanche JL, et al. ���Diagnosis of Creutzfeldt-Jakob disease. Effect of clinical criteria on incidence estimates. Neurology 2000;54:1095-9.

  43. Will RG, Ironside JW, Zeidler M. A new variant of Creutzfeldt- Jakob disease in the UK. Lancet 1996;347:921-5.

  44. Escudero J, Torrella. Cronología de la nueva variante de la enfermedad de Creutzfeldt-Jakob. Rev Neurol 2000;31:141-7.

  45. Spencer M, Knight R, Will RG. First hundred cases of variant Creutzfeldt-Jakob disease: retrospective case note review of early psychiatric and neurological features. BMJ 2002;324:1479-82.

  46. Gonzalo-Pascual I, Cuadrado-Corrales N. Neuropatología de la nueva variante de la enfermedad de Creutzfeldt-Jakob. Rev Neurol 2000;31:160-1.

  47. Zerr I, Pocchiari M, Collins S, et al. Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology 2000;55:811-5.

  48. Ortega-Albás JJ, Serrano-García AL. Neurofisiología de la enfermedad de Creutzfeldt-Jakob. Rev Neurol 2003;36:376-80.

  49. Geschwind M, Martindace J, Miller D. Challenging the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt-Jakob disease. Arch Neurol 2003;60:813-6.

  50. Aksamit A, Preissner C, Homburger H. Quantitation of 14-3-3 and neuron-specific enolase proteins in CSF in Creutzfeldt- Jakob disease. Neurology 2001;57:728-30.

  51. Otto M, Wiltfang J, Cepek L, et al. Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 2002;58:192-7.

  52. Shia Y, Miyazawa K, Sato S, et al. Diffusion-weighted MRI abnormalities as an early diagnostic marker for Creutzfeldt- Jakob disease. Neurology 2004;63:443-9.

  53. Meissner B, Köhler K, Körtner K, et al. Sporadic Creutzfeldt- Jakob disease, magnetic resonance imaging and clinical findings. Neurology 2004;63:450-6.

  54. Zeidler M, Sellar RJ, Collie DA, et al. The pulvinar sign of magnetic resonance imaging in variant Creutzfeldt-Jakob disease. Lancet 2000;355:1412-8.

  55. Summers D, Collie D, Zeidler M, et al. The pulvinar sign in variant Creutzfeldt-Jakob disease. Arch Neurol 2004;61:446-7.

  56. Head MW, Kouverianou E, Taylor E, et al. Evaluation of urinary PrPsc as a diagnostic test for sporadic, variant and familial Creutzfeldt-Jakob disease. Neurology 2005;64:1794-6.

  57. Zanusso G, Ferrari S, Cardons F, et al. Detection of pathologic prion protein in the olfactory epithelium in sporadic Creutzfeldt- Jakob disease. N Engl J Med 2033;348:711-9.

  58. Stoeck K, Bodemer M, Ciesielczyk B, et al. Interleukin 4 and interleukin 10 levels are elevated in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Arch Neurol 2005;62(10):1591-4.

  59. Zerr I, Poser S. Clinical diagnosis and diferential diagnosis of Creutzfeldt-Jakob disease and the new variant Creutzfeldt- Jakob disease: with special emphasis on laboratory tests. APMIS 2002;110(1):88-98.

  60. Aguzzi A, Heikenwalder M, Miele G. Progress and problems in the biology, diagnosis and therapeutics of prion disease. J Clin Invest 2004;114:153-60.

  61. Mayor S. News: small improvement seen in teenager with new variant Creutzfeldt-Jakob disease. BMJ 2003;327:765.




2020     |     www.medigraphic.com